# Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma

> **NCT05039281** · PHASE1,PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 6 (estimated)

## Conditions studied

- Recurrent Glioblastoma
- Recurrent Gliosarcoma

## Interventions

- **BIOLOGICAL:** Atezolizumab
- **DRUG:** Cabozantinib

## Key facts

- **NCT ID:** NCT05039281
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-09-23
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2025-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05039281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05039281, "Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05039281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*